Drug discovery in pharmaceutical industry: Productivity challenges and trends

Drug Discovery Today

Volumn 17, Issue 19-20, 2012, Pages 1088-1102

  Khanna, Ish ^a  

^a Kareus Therapeutics   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; CANCER THERAPY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEGENERATIVE DISEASE; DRUG APPROVAL; DRUG COMPETITION; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG PENETRATION; DRUG TARGETING; FUNDING; HEALTH CARE FACILITY; HUMAN; HUMAN GENOME; MEDICAL RESEARCH; NEUROIMAGING; NONHUMAN; PROBABILITY; PRODUCTIVITY; PUBLIC-PRIVATE PARTNERSHIP; QUALITY CONTROL; REVIEW; STRUCTURAL GENOMICS; TRANSLATIONAL RESEARCH; TREND STUDY;

ANIMALS; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; DRUG INDUSTRY; EFFICIENCY; HUMANS;

EID: 84866739808     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.05.007     Document Type: Review

References (34)

1. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
2. A. Mullard 2010 FDA drug approvals Nat. Rev. Drug Discov. 10 2011 82 85
3. L.J.S. Kunsten Drug discovery management, small is beautiful: why a number of companies get it wrong? Drug Discov. Today 16 2011 476 484
4. A.M. Thayer Emerging strategies Chem. Eng. News 2011 15 20
5. J.A. Vernon Drug development costs when financial risk is measured using the Fama-French three-factor model Health Econ. 19 2010 1002 1005
6. A. Mullard 2011 in reflection Nat. Rev. Drug Discov. 11 2012 6 8
7. FY 2011 Innovative drug approvals. US Food and Drug Administration Report, 2011, 1-29
8. J.L. LaMattina The impact of mergers on pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 559 560
9. L. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
10. A. Graul Overcoming the obstacles in the pharma/biotech industry: 2008 update Drug News Perspect. 22 2009 39 51
11. A. Graul Overcoming the obstacles in the pharma/biotech industry: 2009 update Drug News Perspect. 23 2010 48 63
12. A. Graul The year's new drugs & biologics, 2010 Drugs Today (Barc.) 47 2011 27 51
13. J. Arrowsmith Phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10 2011 328
14. J. Arrowsmith Phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10 2011 87
15. D.C. Swinney, and J. Anthony How were medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
16. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
17. M.R. Andersen Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590
18. S. Andersson Making medicinal chemistry more effective - application of lean sigma to improve processes, speed and quality Drug Discov. Today 14 2009 598 604
19. N.A. Meanwell Synopsis of some recent tactical application of bioisosteres J. Med. Chem. 54 2012 2529 2591
20. M.P. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 51 2008 817 834
21. E.N. Bonabeau A more rational approach to new product development Harvard Bus. Rev. 86 2008 96 102
22. R. Kneller The importance of new companies for drug discovery: origins of a decade of new drugs Nat. Rev. Drug Discov. 9 2010 867 882
23. M. Fieldman TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases Nat. Med. 9 2003 1245 1250
24. M. Goldman Reflections on the innovative medicines initiative Nat. Rev. Drug Discov. 10 2011 321 322
25. P. Talega Open innovation share or die Drug Discov. Today 14 2009 2003 2005
26. C.J. Tralau-Stewart Drug-discovery: new models for industry-academic partnerships Drug Discov. Today 14 2009 95 101
27. A. Mullard Partnering between pharma peers on the rise Nat. Rev. Drug Discov. 10 2011 561 562
28. A.M. Thayer Shifting generics to the super side Chem. Eng. News 2011 22 26
29. A. Persidis Systematic repositioning using MoA to map all drugs against all diseases The Drug Repositioning Conference San Francisco, July 13-14 2011
30. T.L. Doan The future of drug repositioning: old drugs, new opportunities Annu. Rep. Med. Chem. 46 2011 385 401
31. A. Mullard Could pharma open its drug freezers Nat. Rev. Drug Discov. 10 2011 399 400
32. R. Huang The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci. Transl. Med. 3 2011 80ps16
33. F.L. Douglas The case for entrepreneurship in R&D in the pharmaceutical industry Nat. Rev. Drug Discov. 9 2010 683 689
34. N. Taleb The Black Swan: The Impact of the Highly Improbable 2007 Random House